| name | icsm-tt-plus-pde5i-nonresponders |
| description | Recommends adding testosterone therapy to phosphodiesterase‑type‑5 inhibitor (PDE5i) for men with erectile dysfunction who do not respond to PDE5i monotherapy. Triggered when a patient reports inadequate response to sildenafil, tadalafil, or vardenafil and the clinician considers whether to add testosterone or pursue combination therapy. |
Combine testosterone with PDE5 inhibitors for non-responders to PDE5i alone
STEP 1 — Gather Information
Collect erectile dysfunction history, details of PDE5i use (dose, frequency, response), symptoms suggestive of hypogonadism (low libido, fatigue, decreased morning erections), and obtain a morning fasting total testosterone level; also note comorbidities and fertility intentions.
STEP 2 — Rule In / Rule Out
Determine if the patient is hypogonadal: total testosterone <12 nmol/L (<350 ng/dL) and symptomatic; if yes, proceed to step 3, otherwise testosterone therapy is not indicated for ED.
STEP 3 — Classify or Stratify
Among hypogonadal men, classify the erectile dysfunction response to PDE5i as non‑responder (inadequate erection hardness or satisfaction after an adequate trial) or responder (satisfactory response).
STEP 4 — Decide
For hypogonadal PDE5i non‑responders, initiate testosterone therapy in addition to continuing the PDE5i; for responders, continue PDE5i monotherapy alone.
Clinical Guardrails / Mimics / Pitfalls
Do not use testosterone monotherapy for ED unless the patient has mild ED and an absolute demonstration of hypogonadism; avoid starting testosterone without confirming low levels; monitor hematocrit (<54%), PSA, and digital rectal exam per guidelines; be cautious in men with recent cardiovascular events or those seeking fertility, as testosterone can suppress spermatogenesis.
Concrete Clinical Example
A 58‑year‑old man reports suboptimal erections with sildenafil 50 mg PRN, low libido, and fatigue; morning total testosterone is 9 nmol/L; after confirming hypogonadism, testosterone gel is added to his sildenafil regimen, and at 3‑month follow‑up he reports improved erections and libido.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, DOI: 10.1093/sxmrev/qeaf036
